Delta Diagnostics

The company develops label-free, multiplexed biosensing instruments based on photonic integrated circuits for real-time detection of biomolecular interactions. Its technology enables assay developers, academic researchers, and pharma scientists to validate biomarker panels and accelerate drug development by providing kinetic screening and antibody selection data. The platform aims to reduce the cost of ownership for high-performance detection compared to traditional methods like ELISA.